Home/Filings/4/0001021771-23-000086
4//SEC Filing

Silva Francisco 4

Accession 0001021771-23-000086

CIK 0001505497other

Filed

Aug 30, 8:00 PM ET

Accepted

Aug 31, 1:54 PM ET

Size

19.4 KB

Accession

0001021771-23-000086

Insider Transaction Report

Form 4
Period: 2023-08-31
Silva Francisco
VP of Research and Development
Transactions
  • Purchase

    Common Stock

    2023-08-31$2.22/sh+4,954$10,998164,644 total
Holdings
  • Common Stock

    (indirect: By IRA)
    12,136
  • Stock Option

    Exercise: $3000.00Exp: 2024-10-23Common Stock (9 underlying)
    9
  • Stock Option

    Exercise: $3000.00Exp: 2025-09-04Common Stock (6 underlying)
    6
  • Stock Option

    Exercise: $3000.00Exp: 2024-02-18Common Stock (3 underlying)
    3
  • Stock Option

    Exercise: $3000.00From: 2014-03-12Exp: 2024-03-11Common Stock (1 underlying)
    1
  • Stock Option

    Exercise: $3000.00Exp: 2026-06-10Common Stock (15 underlying)
    15
  • Stock Option

    Exercise: $3000.00Exp: 2023-10-04Common Stock (1 underlying)
    1
  • Stock Option

    Exercise: $3000.00Exp: 2027-07-12Common Stock (20 underlying)
    20
  • Stock Option

    Exercise: $5.08Exp: 2031-03-18Common Stock (293,479 underlying)
    293,479
  • Stock Option

    Exercise: $5.08Exp: 2031-11-04Common Stock (42,059 underlying)
    42,059
  • Stock Option

    Exercise: $2.91Exp: 2033-02-17Common Stock (106,762 underlying)
    106,762
  • Stock Option

    Exercise: $3000.00Exp: 2028-10-29Common Stock (25 underlying)
    25
Footnotes (5)
  • [F1]Includes 48,912 shares received pursuant to an unvested restricted stock unit grant. Such shares vest on March 18, 2024.
  • [F2]The option is currently exercisable.
  • [F3]The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 and 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.
  • [F4]The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 and 21,029 shares in eight nearly equal quarterly installments beginning November 4, 2022 and continuing every three months thereafter until fully vested.
  • [F5]The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested.

Documents

1 file

Issuer

BioRestorative Therapies, Inc.

CIK 0001505497

Entity typeother

Related Parties

1
  • filerCIK 0001527241

Filing Metadata

Form type
4
Filed
Aug 30, 8:00 PM ET
Accepted
Aug 31, 1:54 PM ET
Size
19.4 KB